Near-total overlap of memberships, plus the rising importance of specialty pharma to all pharma distribution, seem to be the drivers
On the heels of its annual Business & Leadership meeting, the Healthcare Distribution Management Assn. (Arlington, VA) has announced that the Specialty & Biotech Distributors Assn. (SBDA) has merged with it. There will be a new council within HDMA, the Specialty & Biotech Distribution Council, which will be charged with guiding the association’s advocacy and industry relations efforts on issues such as reimbursement, pedigree, and risk evaluation and mitigation strategies (REMS) as they relate specifically to specialty pharmaceutical distribution.
SBDA was formed a few years ago, apparently (its website has already been shut down) to advocate on behalf of its members on issues relating to Average Sales Price (ASP), reimbursement for distribution services and Medicare policy. The real wonder is why it was separate from HDMA at all: it members were mostly HDMA members as well, including the Big Three distributors, US Oncology and a handful of other specialty distributors. All of this points to rising importance of specialty pharmaceutical (and pharmacy) services, which relate primarily to chronic care drugs that need the intercession of healthcare professionals to administer.
“Bringing our associations together to align our advocacy efforts will provide the healthcare distribution industry with a single, definitive voice on its fastest-growing business segment,” said John M. Gray, President and CEO, HDMA. “This will further leverage the distributor’s role as the central, vital link in the healthcare supply chain. We will be better poised to bring together the entire supply chain from manufacturers to healthcare providers, to improve the delivery of specialty drugs to the patients who need them most.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.